{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:36:43Z","timestamp":1648834603395},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/crd.0b013e31815e7213","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T08:01:28Z","timestamp":1202716888000},"page":"89-94","source":"Crossref","is-referenced-by-count":0,"title":["GP IIb\u2013IIIa Inhibitors Administered Upstream"],"prefix":"10.1097","volume":"16","author":[{"given":"Pierluigi","family":"Tricoci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L Kristin","family":"Newby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes, The PURSUIT Trial Investigators.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction, Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.100.14.1509","article-title":"Angiographic findings in patients with refractory unstable angina according to troponin T status.","volume":"100","author":"Heeschen","year":"1999","journal-title":"Circulation"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.","volume":"340","author":"Hamm","year":"1999","journal-title":"N Engl J Med"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","article-title":"Benefit of glycoprotein IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the PARAGON-B troponin T substudy.","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(99)10285-X","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.","volume":"354","author":"Heeschen","year":"1999","journal-title":"Lancet"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0735-1097(02)02666-9","article-title":"Intravenous glycoprotein IIb\/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.","volume":"41","author":"Karvouni","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.","volume":"100","author":"Boersma","year":"1999","journal-title":"Circulation"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0735-1097(03)00514-X","article-title":"Early use of glycoprotein IIb\/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4.","volume":"42","author":"Peterson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1197\/j.aem.2004.11.029","article-title":"Early glycoprotein IIb\/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.","volume":"12","author":"Hoekstra","year":"2005","journal-title":"Acad Emerg Med"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/01.CIR.100.15.1609","article-title":"Intracoronary thrombus and platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.","volume":"100","author":"Zhao","year":"1999","journal-title":"Circulation"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.amjcard.2004.04.066","article-title":"Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).","volume":"94","author":"Gibson","year":"2004","journal-title":"Am J Cardiol"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1197\/aemj.9.11.1146","article-title":"Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department. The CRUSADE Initiative.","volume":"9","author":"Hoekstra","year":"2002","journal-title":"Acad Emerg Med"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1001\/jama.295.16.1912","article-title":"Association between hospital process performance and outcomes among patients with acute coronary syndromes.","volume":"295","author":"Peterson","year":"2006","journal-title":"JAMA"},{"key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.amjcard.2006.12.066","article-title":"Timing of glycoprotein IIb\/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (Results from CRUSADE).","volume":"99","author":"Tricoci","year":"2007","journal-title":"Am J Cardiol"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ahj.2006.04.015","article-title":"The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes.","volume":"152","author":"Mehta","year":"2006","journal-title":"Am Heart J"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","article-title":"The early glycoprotein IIb\/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome\u2014study design and rationale.","volume":"149","author":"Giugliano","year":"2005","journal-title":"Am Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045415-200803000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:56:22Z","timestamp":1618034182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200803000-00005"}},"subtitle":["Evidence for Improved Outcomes With Conventional and Newer Antithrombotic Agents?"],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e31815e7213","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}